enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Iloprost - Wikipedia

   en.wikipedia.org/wiki/Iloprost

   Iloprost, sold under the brand name Ventavis among others, is a medication used to treat pulmonary arterial hypertension (PAH), scleroderma, Raynaud's phenomenon, frostbite, and other conditions in which the blood vessels are constricted and blood cannot flow to the tissues. [4] Iloprost is a prostacyclin mimetic. [1]

3. Pulmonary drug delivery - Wikipedia

   en.wikipedia.org/wiki/Pulmonary_drug_delivery

   Pulmonary drug delivery is mainly utilized for topical applications in the lungs, such as the use of inhaled beta-agonists, corticosteroids and anticholinergic agents for the treatment of asthma and COPD, the use of inhaled mucolytics and antibiotics for the treatment of cystic fibrosis (CT) and respiratory viral infections, [1] and the use of inhaled prostacyclin analogs for the treatment of ...

4. Treprostinil - Wikipedia

   en.wikipedia.org/wiki/Treprostinil

   Treprostinil, sold under the brand names Remodulin for infusion, Orenitram for oral, and Tyvaso for inhalation, is a vasodilator that is used for the treatment of pulmonary arterial hypertension. [6] Treprostinil was approved for use in the United States in May 2002. [7]

5. US FDA still reviewing Liquidia's inhaled blood pressure drug

   www.aol.com/news/us-fda-still-reviewing...

   US FDA still reviewing Liquidia's inhaled blood pressure drug. January 25, 2024 at 6:17 AM ... The drug was granted tentative approval in 2021 to treat pulmonary arterial hypertension (PAH) to ...

6. Liquidia's inhaled drug fails to get traditional approval in ...

   www.aol.com/news/us-fda-grants-tentative...

   (Reuters) -The U.S. Food and Drug Administration on Monday delayed traditional approval for Liquidia Corp's inhaled drug for types of lung disorders, and allowed only tentative clearances, sending ...

7. Soluble guanylate cyclase stimulator - Wikipedia

   en.wikipedia.org/wiki/Soluble_guanylate_cyclase...

   Soluble guanylate cyclase (sGC) stimulators are a class of drugs developed to treat heart failure, pulmonary hypertension, and other diseases. The first-in-class medication was riociguat, approved in 2013 for pulmonary hypertension. [1] [2] They have also been investigated for hypertension, systemic sclerosis, and sickle cell disease. [3] [1]